Controlling Brain Cells With Light: Ethical Considerations for Optogenetic Clinical Trials

AJOB Neuroscience

Volumn 5, Issue 3, 2014, Pages 3-11

  Gilbert, Frederic ^a   Harris, Alexander R ^b   Kapsa, Robert M I ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

clinical trials; first in human; genetics; human subjects; nervous system; neurodegenerative disorder; neurosurgery; optogenetics; Phase 1

Indexed keywords

EID: 84902579985     PISSN: 21507740     EISSN: 21507759     Source Type: Journal    
DOI: 10.1080/21507740.2014.911213     Document Type: Article

References (74)

1. Abel, J.J., L.G. Rowntree, and B.B. Turner. 1913. On the removal of diffusible substances from the circulating blood by means of dialysis. Transactions of the Association of American Physicians 28: 51-54.
2. Asokan, A., D.V. Schaffer, and R. Jude Samulski. 2012. The AAV vector toolkit: Poised at the clinical crossroads. Molecular Therapy 20: 699-708.
3. Bainbridge, J.W., A. Mistry, F.C. Schlichtenbrede, et al. 2003. Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina. Gene Therapy 10: 1336-1344.
4. Bainbridge, J.W., A.J. Smith, S.S. Barker, et al. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. New England Journal of Medicine 358: 2231-2239.
5. Bretzner, F., F. Gilbert, F. Baylis, and R. Brownstone. 2011. Target populations for first-in-human embryonic stem cell research in spinal cord injury? Cell Stem Cell 8: 468-475.
6. Bi, A., et al., 2006. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 50: 23-33.
7. Boyden, E.S. 2010. A history of optogenetics: The development of tools for controlling brain circuits with light. F1000 Biology Reports 3: 11.
8. Boyden, E.S., et al. 2005. Millisecond-timescale, genetically targeted optical control of neural activity. Nature Neuroscience 8: 1263-1268.
9. Buchen, L. 2010. Neuroscience: Illuminating the brain. Nature 465: 26-28.
10. Businesswire. 2013. RetroSense Therapeutics announces notice of allowance for new u.s. patent application broadly covering optogenetic approaches to vision restoration. http://www.businesswire.com/news/home/20130305006250/en/RetroSense-Therapeutics-Announces-Notice-Allowance-U.S.-Patent
11. Cideciyan, A.V., W.W. Hauswirth, T.S. Aleman, et al. 2009. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Human Gene Therapy 20(9): 999-1004.
12. Clinicaltrials.gov. n.d. Glossary of clinical trials terms. U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/about-studies/glossary (accessed May 6, 2014).
13. Council for International Organizations of Medical Sciences. 2002. International ethical guidelines for biomedical research involving human subjects. Council for International Organizations of Medical Sciences (CIOMS). www.cioms.ch/publications/layout_guide2002.pdf
14. Covington, H.E., M.K. Lobo, I. Maze, et al. 2010. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. Journal of Neuroscience 30: 16082-16090.
15. Deisseroth, K., 2010. Optogenetics: Controlling the brain with light. Scientific American. Available at: http://www.scientificamerican.com/article/optogenetics-controlling/ (accessed May 6, 2014).
16. Deisseroth, K. 2011. Optogenetics. Nature Methods 8: 26-29.
17. Editorial. 2011. Method of the year 2010. Nature Methods 8. doi:10.1038/nmeth.f.321.
18. FDA.gov. n.d.-a. FDA approves new treatment for gastrointestinal and kidney cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108583.htm (accessed May 6, 2014).
19. FDA.gov. n.d.-b. FDA approves first retinal implant for adults with rare genetic eye disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm339824.htm (accessed May 6, 2014).
20. Fenno, L., O. Yizhar, and K. Deisseroth. 2011. The development and application of optogenetics. Annual Review of Neuroscience 34: 389-412.
21. Fiandaca, M., J. Forsayeth, and K. Bankiewicz. 2008. Current status of gene therapy trials for Parkinson's disease. Experimental Neurology 209: 51-57.
22. Fradot, M., V. Busskamp, V. Forster, et al. 2011. Gene therapy in ophthalmology: Validation on cultured retinal cells and explants from postmortem human eyes. Human Gene Therapy 22(5): 587-593
23. Gilbert, F. 2012. The burden of normality: From 'chronically ill' to 'symptom free'. New ethical challenges for deep brain stimulation postoperative treatment. Journal of Medical Ethics 38: 408-412. doi:10.1136/medethics-2011-100044
24. Gilbert, F. 2013a. Deep brain stimulation for treatment resistant depression: Postoperative feelings of self-estrangement, suicide attempt and impulsive-aggressive behaviours. Neuroethics. Online First doi:10.1007/s12152-013-9178-8
25. Gilbert, F. 2013b. Nano-bionic devices for purpose of cognitive enhancement: Toward a preliminary ethical framework. In Cognitive enhancement: An interdisciplinary perspective, Trends in augmentation of human performance 1, ed. E. Hildt and A. Franke, 125-138. Dordrecht: Springer Science Business Media.
26. Gilbert, F., and B. Baertschi. 2011. Neuroenhancement: Much ado about nothing? American Journal of Bioethics: Neuroscience, 2(4): 45-47.
27. Gilbert, F., A. Harris, and R. Kapsa. 2012. Efficacy testing as a primary purpose of Phase 1 clinical trials: Is it applicable to first-in-human bionics and optogenetics trials? AJOB Neuroscience 3(2): 20-22.
28. Gilbert, F., A. Vranic, and S. Hurst. 2013. Involuntary & voluntary invasive brain surgery: ethical issues related to acquired aggressiveness. Neuroethics 6: 115-128. doi:10.1007/s12152-012-9161-9. Epub 2012.
29. Gradinaru, V., M. Mogri, K.R. Thompson, J.M. Henderson, and K. Deisseroth. 2009. Optical deconstruction of parkinsonian neural circuitry. Science 324: 354-359.
30. Guo, X., and L. Huang. 2012. Recent advances in nonviral vectors for gene delivery. Accounts of Chemical Research 45(7): 971-979.
31. Han, X., X. Qian, J.G. Bernstein, et al. 2009. Millisecondtimescale optical control of neural dynamics in the nonhuman primate brain. Neuron 62: 191-198.
32. Hess, P. 2012. Intracranial stem cell-based transplantation: reconsidering the purpose and ethical justification of Phase 1 clinical trials in light of irreversible intervention in the brain. AJOB Neuroscience 3: 3-13.
33. Hey, S.P., and J. Kimmelman. 2013. Ethics, error, and initial trials of efficacy. Science Translational Medicine 5: 184fs16.
34. Jakobsson, J., and C. Lundberg. 2006. Lentiviral vectors for use in the central nervous system. Molecular Therapy 13: 484-493.
35. Jia, Z., et al., 2011. Stimulating cardiac muscle by light: Cardiac optogenetics by cell delivery. Circulation: Arrhythmia and Electrophysiology. 4: 753-760.
36. Kimmelman, J. 2009. Gene transfer and the ethics of first-in-human experiments: Lost in translation. New York, NY: Cambridge University Press.
37. Kimmelman, J. 2012. A theoretical framework for early human studies: Uncertainty, intervention ensembles, and boundaries. Trials 13: 173. http://www.trialsjournal.com/content/13/1/173
38. Kimmelman, J., and A.J. London. 2011. Predicting harms and benefits in translational trials: Ethics, evidence, and uncertainty. PLoS Medicine 8(3): e1001010. doi:10.1371/journal.pmed.1001010
39. Kimmelman, J., A.J. London, B. Ravina, et al. 2009. Launching invasive, first-in-human trials against Parkinson's disease: Ethical considerations. Movement Disorders 241: 893-901.
40. Kolff, W.J., H.T. J. Berk, M. ter Welle, A.J. W. van der Ley, E.C. van Dijk, and J. van Noordwijk. 1944. The artificial kidney: A dialyser with great area. Acta Medica Scandinavica CXVII: 121-134.
41. Kravitz, A.V., B.S. Freeze, P.R. Parker, et al. 2010. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466: 622-626.
42. Lai, C.-M., W.-Y. Shen, M. Brankov, et al. 2005. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Molecular Therapy 12(4): 659-668.
43. Langreth, R. 2010. The light fantastic. Forbes Magazine,. July 19. Available at: http://www.openoptogenetics.org/images/b/bf/The_Light_Fantastic.pdf (accessed May 6, 2014).
44. Mandel, R.J., C. Burger, and R.O. Snyder. 2008. Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and clinical grade production. Experimental Neurology 209: 58-71.
45. Mandel, R.J., et al. 2006. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molecular Therapy 13: 463-483.
46. Mather, L. 2011. $12.5M grant supports research in optogenetics, microscopy, and tumor detection. BioOptics World,. October 10. http://www.bioopticsworld.com/articles/2011/10/grant-supports-research.html Last retrieved April 2012
47. Matsui, K. 2013. Mind control with optogenetic mice: Exploring the causal relationships between brain activity and the mind. Brain Nerve 65(6): 609-621.
48. McNeill, P.M. 1993. The ethics and politics of human experimentation. New York, NY: Cambridge University Press
49. Miesenböck, G. 2009. The optogenetic catechism. Science 326(5951): 395-399. Available at: http://edition.cnn.com/2013/01/06/opinion/mlodinow-science-frontier/ (accessed May 6, 2014).
50. Mlodinow, L. 2013. How to 'take over' a brain. CNN,. January 7. Available at: http://edition.cnn.com/2013/01/06/opinion/mlodinow-science-frontier/ (accessed May 6, 2014).
51. Narfstrom, K., M.L. Katz, M. Ford, T.M. Redmond, E. Rakoczy, and R. Bragadottir. 2003. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. Journal of Heredity 94(1): 31-37.
52. Nordmann, A. 2007. If and then: A critique of speculative nanoethics. Nanoethics 1: 31-46.
53. Perlmutter, J.S., and J.W. Mink. 2006. Deep brain stimulation. Annual Review of Neuroscience 29: 229-257.
54. Sidor, M.M. 2012. Psychiatry's age of enlightenment: Optogenetics and the discovery of novel targets for the treatment of psychiatric disorders. Journal of Psychiatry & Neuroscience 37(1): 4-6.
55. Simonelli, F., A.M. Maguire, F. Testa, et al. 2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Molecular Therapy 18(3): 643-650.
56. Sohal, V.S., F. Zhang, O. Yizhar, and K. Deisseroth. 2009. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459: 698-702.
57. Starkman, R. 2012. Optogenetics: A novel technology with questions old and new. Huffington Post,. July 26. Available at: http://www.huffingtonpost.com/ruth-starkman/optogenetics-a-new-techno_b_1700219.html (accessed May 6, 2014).
58. The Brain Prize. n.d. http://www.thebrainprize.org
59. The news staff. 2010. Stepping away from the trees for a look at the forest. Science 330: 1612-1613.
60. The White House. n.d. http://www.whitehouse.gov/infographics/brain-initiative
61. Tsilidis, K.K., O.A. Panagiotou, E.S. Sena, et al. 2013. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biology 11(7): e1001609. doi:10.1371/journal.pbio.1001609
62. Tsai, H.C., F. Zhang, A. Adamantidis, et al. 2009. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science 324: 1080-1084.
63. World Medical Association. 2008. WMA Declaration of Helsinki-Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html
64. Yizhar, O., et al. 2011. Optogenetics in neural systems. Neuron 71: 9-34.
65. YouTube. n.d. Fiberoptic control of locomotion in chr2 mouse. https://www.youtube.com/watch?v=v7uRFVR9BPU
66. Zorzos, A.N., J. Scholvin, E.S. Boyden, and C.G. Fonstad. 2012. Three-dimensional multiwaveguide probe array for light delivery to distributed brain circuits. Optics Letters 37(23): 4841-4843.
67. Gilbert, F. and S. Dodds. 2013. How to turn ethical neglect into ethical approval? AJOB Neuroscience 4(2): 59-60. doi:10.1080/21507740.2013.782914.
68. Gilbert, F. and E. Goddard. 2014. Thinking ahead too much: Speculative ethics and implantable brain devices. AJOB Neuroscience 5(1): 49-51. doi:10.1080/21507740.2013.863252.
69. Gilbert, F. and D. Ovadia. 2011. Deep brain stimulation in the media: Over-optimistic media portrayals calls for a new strategy involving journalists and scientifics in the ethical debate. Journal of Integrative in Neuroscience 5: 16. doi:10.3389/fnint.2011.00016.
70. Lagali, P.S., D. Balya, G.B. Awatramani, et al. 2008. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nature Neuroscience 11: 667-675.
71. Rojahn, S.Y. 2012. Company aims to cure blindness with optogenetics. Available at: http://www.technologyreview.com/news/429010/company-aims-to-cure-blindness-with-optogenetics/ (accessed May 6, 2014).
72. Schlaepfer, T.E. and J. Fins. 2010. Deep brain stimulation and the neuroethics of responsible publishing, when one is not enough. JAMA 303: 775-776.
73. Smith, K. 2013.Neuroscience: Method man. Nature 497(7451):550-552. doi:10.1038/497550a.
74. Gilbert, F. 2013c. Deep brain stimulation and postoperative suicidability among treatment resistant depression patients: Should eligibility protocols exclude patients with history of suicide attempts and anger/impulsivity? AJOB Neuroscience 4(1): 28-35. doi:10.1080/21507740.2012.740143.